American Diabetes Association
Laugesen_Supplementary_material_v2.0.pdf (1.51 MB)

Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study

Download (1.51 MB)
posted on 2022-04-27, 13:48 authored by Christian Laugesen, Ajenthen G. Ranjan, Signe Schmidt, Kirsten Nørgaard
Objective: To compare the efficacy of low-dose subcutaneous dasiglucagon with oral glucose for prevention of insulin-induced hypoglycemia in people with type 1 diabetes.

Research Design and Methods: Twenty adults with type 1 diabetes using either multiple daily injection or insulin pump therapy completed a phase 2, randomized, 3-arm cross-over study. On each study visit, an individualized subcutaneous insulin bolus was administered aiming for a plasma glucose concentration (PG) of 3.0 mmol/L (54 mg/dL). When a PG of 4.5 mmol/L (81 mg/dL) was reached, either 15 g oral glucose from dextrose tablets (CHO), 80 µg dasiglucagon (D80) or 120 µg dasiglucagon (D120) was administered. PG was measured frequently for the following 180 minutes.

Results: Hypoglycemia (<3.9 mmol/L (70 mg/dL)) occurred in 10 participants after CHO, in 5 after D80 and in 4 after D120 (CHO vs D80, p=0.096; CHO vs D120, p=0.034). Time spent in hypoglycemia (<3.9 mmol/L (70 mg/dL)) was 14%, 7% and 6% for CHO, D80, and D120, respectively (p=0.273). The median time (95%CI) from intervention to first increase in PG of 1.1 mmol/L (20 mg/dL) was 30 (25-50), 15 (15-20) and 15 (15-20) minutes for CHO, D80 and D120 (CHO vs D80, p=0.006; CHO vs D120, p=0.003). Episodes of nausea were numerically, but not significantly, higher after dasiglucagon administration. No significant differences in visual analog scale-assessed adverse effects were observed between interventions.

Conclusions: Low-dose dasiglucagon safely and effectively prevented insulin-induced hypoglycemia with a faster glucose-elevating profile than oral glucose.


Steno Diabetes Center Copenhagen is the sponsor of this investigator-initiated trial. Zealand Pharma provided financial support to the conduct of the study, supplied the study medication, and analyzed the plasma dasiglucagon concentration of the samples.


Usage metrics

    Diabetes Care


    Ref. manager